Catalyst overview
Research summary
This catalyst tracks a Phase 2b update for Bezisterim (NE3107) in Early Parkinson's disease. The expected timing is based on the latest available company guidance and may change.
SUNRISE-PD trial. 4/16/25- Initiated Ph2b trial, patient enrollment ongoing. Topline data in late 2025 or early 2026. 6/24/25- Presents trial overview at ATMRD.01/08/26:- SUNRISE-PD completed enrollment of 60 early Parkinson’s patients; topline Phase 2b results expected in H1 2026. 02/12/26:- SUNRISE-PD enrollment of 60 early Parkinson’s patients confirmed; topline Ph2b results now expected Mid-2026. 03/12/26:- AD/PD 2026 poster on SUNRISE-PD baseline characteristics. Topline Phase 2b results expected Mid-2026. 04/14/26:- AAN 2026 poster Apr 20 on SUNRISE-PD baseline demographics. Topline Phase 2b results expected Mid-2026. 05/18/26:- SUNRISE-PD last patient visit completed; topline Phase 2b results expected Q3 2026. 08/06/26:- SUNRISE-PD topline Ph2b results reported; met endpoints. Conference call Aug 12, 2026.
Verification
Confirm timing and program details against the company announcement or filing.